York Charles N II 4

What Happened
Charles N. York II, Day One Biopharmaceuticals' Chief Operating Officer and Chief Financial Officer, was granted a total of 314,000 derivative equity awards on January 30, 2026: 188,000 option-type awards and 126,000 restricted stock units (RSUs). The reported acquisition price for both grants is $0.00 (i.e., no cash was paid at grant).

Key Details

• Transaction date: 2026-01-30 (Form 4 filed same day).
• Grants: 188,000 option units (derivative); 126,000 RSUs (derivative). Total = 314,000 awards.
• Reported cash consideration: $0.00 for both grants (award/compensation, not an open-market purchase).
• Shares owned after transaction: not specified in this Form 4 filing.
• Notable footnotes:
  • F1: The 188,000 option vests 1/48th monthly starting Feb 28, 2026, contingent on continued service.
  • F2–F4: Each RSU represents a right to one share; the 126,000 RSUs vest 1/16th quarterly (Feb 15, May 15, Aug 15, Nov 15) subject to continued service; RSUs do not expire but are either vested or canceled.
• Filing timeliness: Reported and filed for the same report date (no late filing indicated).

Context
These are compensation grants (awards) rather than open-market purchases or sales. They create a contingent right to shares that will vest over time based on service; they do not represent immediate ownership of shares unless and until vested/settled. For retail investors, award grants are common executive compensation and do not by themselves indicate buying or selling sentiment.